INTERNATIONAL & TRADE LAW

DETAILED EXPLANATION WITH CASE LAWS

1. Introduction

International and Trade Law refers to the body of legal rules, principles, treaties and agreements governing international commercial relationships between countries. It regulates the movement of goods, services, technology, capital, intellectual property and investments across national borders.

In biotechnology and life sciences, international trade law plays an important role in regulating pharmaceutical products, vaccines, genetically modified organisms (GMOs), biological materials, medical technologies and scientific innovations.

Its primary objective is to promote fair international trade while protecting public health, environmental safety, biodiversity and intellectual property rights.

2. Meaning and Scope of International and Trade Law

International and Trade Law establishes legal standards for commercial activities between countries and international organizations.

Its scope includes:

International trade in pharmaceutical products.

Import and export of biotechnology materials.

Intellectual property protection.

International technology transfer.

Regulation of genetically modified organisms.

International transfer of biological resources.

Pharmaceutical patent protection.

Foreign investment in biotechnology.

Prevention of unfair trade practices.

International scientific cooperation.

3. Major International Legal Frameworks

A. World Trade Organization (WTO)

The World Trade Organization was established in 1995 to regulate international trade and promote fair commercial relationships between member countries.

Its important agreements include GATT, TRIPS, SPS, TBT and GATS.

B. General Agreement on Tariffs and Trade (GATT 1994)

GATT regulates international trade in goods and aims to reduce unnecessary trade barriers.

Important provisions include:

Article I: Most-Favoured-Nation Treatment.

Article III: National Treatment.

Article XI: General Elimination of Quantitative Restrictions.

Article XX: General Exceptions.

Article XX permits certain measures necessary to protect human, animal or plant life or health, subject to its legal conditions.

C. TRIPS Agreement

The Agreement on Trade-Related Aspects of Intellectual Property Rights establishes minimum international standards for intellectual property protection.

It covers patents, trademarks, copyright, industrial designs and undisclosed information.

Article 27 deals with patentable subject matter, while Article 28 establishes patent rights.

D. SPS Agreement

The Sanitary and Phytosanitary Measures Agreement regulates measures intended to protect human, animal and plant health.

It is relevant to food safety, agricultural biotechnology, imported biological products and genetically modified crops.

E. TBT Agreement

The Technical Barriers to Trade Agreement regulates technical standards, product labelling, packaging and conformity assessment procedures affecting international trade.

4. International Trade Regulation of Biotechnology Products

International trade law regulates biotechnology products through various legal and regulatory mechanisms.

Important areas include:

Pharmaceutical Trade Regulation: Medicines and biological products must meet applicable safety, efficacy and quality requirements.

GMO Regulation: International trade in genetically modified organisms requires consideration of biosafety and environmental protection.

Import and Export Controls: Countries may restrict hazardous biological materials and controlled pathogens.

Technology Transfer: International licensing agreements regulate the transfer of biotechnology inventions and technical knowledge.

Access to Medicines: International law balances patent protection with access to affordable medicines.

5. Important Case Laws

Case 1: European Communities – Measures Affecting the Approval and Marketing of Biotech Products (2006)

Citation: WTO, WT/DS291, WT/DS292 and WT/DS293.

Legal Issue: Restrictions and delays concerning approval and marketing of genetically modified products.

Decision: The WTO Panel examined the European Communities' biotechnology approval procedures and certain national safeguard measures. It found that a general de facto moratorium had been applied during the relevant period and that certain procedures were inconsistent with WTO obligations.

Legal Principle: Biotechnology approval procedures must comply with applicable international trade obligations.

Importance: This case demonstrates the relationship between GMO regulation, scientific risk assessment and international trade.

Case 2: Canada – Patent Protection of Pharmaceutical Products (2000)

Citation: WTO, WT/DS114.

Legal Issue: Whether Canadian pharmaceutical patent legislation complied with the TRIPS Agreement.

Decision: The WTO Panel accepted Canada's regulatory-review exception under Article 30 of TRIPS but found its stockpiling exception inconsistent with TRIPS obligations.

Legal Principle: Limited exceptions to patent rights must satisfy Article 30 of the TRIPS Agreement.

Importance: The case is important for pharmaceutical patents, generic medicines and access to healthcare.

Case 3: United States – Import Prohibition of Certain Shrimp and Shrimp Products (1998)

Citation: WTO, WT/DS58/AB/R.

Legal Issue: Whether restrictions on imported shrimp intended to protect endangered sea turtles violated international trade rules.

Decision: The WTO Appellate Body recognized environmental protection as a legitimate objective under GATT Article XX. However, the original US measure was inconsistent with the introductory requirements of Article XX because of its discriminatory application.

Legal Principle: Environmental protection measures must not be applied in an arbitrary or unjustifiably discriminatory manner.

Importance: This decision is relevant to international trade in environmentally sensitive biological materials.

Case 4: European Communities – Measures Affecting Asbestos and Asbestos-Containing Products (2001)

Citation: WTO, WT/DS135/AB/R.

Legal Issue: Whether France's prohibition on asbestos-containing products violated international trade obligations.

Decision: The WTO Appellate Body upheld the conclusion that the prohibition was justified under GATT Article XX(b), which concerns protection of human life and health.

Legal Principle: Countries may restrict dangerous products to protect public health, subject to applicable international legal requirements.

Importance: The case establishes the importance of public health protection in international trade.

Case 5: United States – Standards for Reformulated and Conventional Gasoline (1996)

Citation: WTO, WT/DS2/AB/R.

Legal Issue: Whether US environmental regulations discriminated against imported gasoline.

Decision: The Appellate Body found that the measure violated the national treatment principle and was not justified under Article XX as applied.

Legal Principle: Environmental regulations must not unfairly discriminate between domestic and imported products.

Importance: This decision is relevant to environmental standards and international biotechnology trade.

Case 6: United States – Measures Concerning the Importation, Marketing and Sale of Tuna and Tuna Products (2012)

Citation: WTO, WT/DS381/AB/R.

Legal Issue: Whether US dolphin-safe labelling requirements discriminated against Mexican tuna products.

Decision: The Appellate Body found the US measure inconsistent with the national treatment obligation under Article 2.1 of the TBT Agreement.

Legal Principle: Technical regulations and labelling requirements must not discriminate against imported products.

Importance: This decision is relevant to GMO labelling and biotechnology product certification.

Case 7: Novartis AG v. Union of India (2013)

Citation: (2013) 6 SCC 1.

Court: Supreme Court of India.

Legal Issue: Whether Novartis could obtain a patent for a new form of the existing cancer medicine imatinib mesylate.

Decision: The Supreme Court rejected the patent claim because it did not satisfy the enhanced therapeutic efficacy requirement under Section 3(d) of the Indian Patents Act, 1970.

Legal Principle: Minor modifications of known substances cannot automatically receive patent protection without satisfying statutory requirements.

Importance: This case is significant for pharmaceutical patents, TRIPS implementation and affordable access to medicines.

6. International Trade Law and Biotechnology Intellectual Property

Intellectual property protection encourages innovation in biotechnology and pharmaceutical industries.

International trade law protects:

Biotechnology patents.

Pharmaceutical inventions.

Genetic technologies.

Scientific research innovations.

Manufacturing processes.

Confidential technical information.

Biotechnology trademarks.

Licensing and technology transfer agreements.

However, intellectual property protection must be balanced against public health, competition and access to essential medicines.

7. International Regulation of Genetically Modified Organisms

The Cartagena Protocol on Biosafety is an important international agreement regulating the safe handling, transfer and use of living modified organisms resulting from modern biotechnology.

Its major objectives include:

Protecting biological diversity.

Preventing environmental harm.

Promoting safe transportation of living modified organisms.

Establishing advance informed agreement procedures for certain transboundary movements.

Encouraging scientific risk assessment.

Promoting international information exchange.

The Cartagena Protocol operates alongside the broader international trade framework.

8. International and Trade Law in the Indian Legal System

India participates in international trade through WTO membership and various bilateral and regional trade agreements.

Important Indian laws include:

1. Foreign Trade (Development and Regulation) Act, 1992: Regulates India's foreign trade and import-export activities.

2. Customs Act, 1962: Governs the import and export of goods and customs procedures.

3. Patents Act, 1970: Provides legal protection for qualifying inventions, including biotechnology inventions.

4. Environment (Protection) Act, 1986: Provides a framework for environmental protection and regulation of hazardous substances and genetically engineered organisms.

5. Foreign Trade Policy: Establishes guidelines for import-export activities and trade promotion.

6. Biological Diversity Act, 2002: Regulates access to biological resources and associated knowledge, benefit-sharing and biodiversity protection.

9. International Trade Dispute Settlement Mechanisms

The WTO provides a structured mechanism for resolving international trade disputes.

Its major stages include:

Consultations between disputing countries.

Establishment of a dispute settlement panel.

Examination of legal issues and evidence.

Issuance and consideration of panel findings.

Implementation of recommendations.

Compliance proceedings where necessary.

These mechanisms help resolve disputes concerning pharmaceutical patents, GMO approvals, discriminatory trade restrictions and technical standards.

10. Relationship Between International Trade Law and Public Health

International trade law recognizes the importance of public health protection.

Countries may adopt appropriate measures to:

Restrict unsafe pharmaceutical products.

Establish vaccine quality standards.

Regulate genetically modified food products.

Prevent the spread of dangerous pathogens.

Control hazardous biological substances.

Protect human, animal and plant health.

However, such measures must comply with applicable international trade obligations.

11. Major Challenges in International and Trade Law

Differences in national regulatory systems.

Intellectual property disputes.

Unequal access to affordable medicines.

Biosafety and environmental concerns.

Trade protectionism.

Unequal technology transfer.

Regulatory fragmentation.

National security and biosecurity concerns.

12. Importance of International and Trade Law in Biotechnology

International and Trade Law:

Encourages international scientific collaboration.

Promotes pharmaceutical trade.

Protects biotechnology patents.

Establishes international trade standards.

Supports access to essential medicines.

Promotes responsible biotechnology development.

Protects biodiversity and environmental interests.

Reduces unnecessary trade barriers.

Encourages foreign investment.

Provides mechanisms for resolving international commercial disputes.

13. Suggestions for Improving International and Trade Law

Harmonization of biotechnology regulatory standards.

Strengthening international biosafety cooperation.

Improving transparency in pharmaceutical approval procedures.

Promoting affordable access to essential medicines.

Encouraging fair technology transfer.

Strengthening intellectual property enforcement.

Developing consistent GMO labelling standards.

Improving biological risk management.

Preventing discriminatory trade restrictions.

Supporting developing countries through technical assistance.

14. Conclusion

International and Trade Law plays a fundamental role in regulating international commercial relationships and promoting cooperation between countries.

In biotechnology and life sciences, it provides the legal framework for international trade in pharmaceutical products, vaccines, genetically modified organisms, biological materials and scientific technologies.

International agreements such as GATT, TRIPS, SPS and TBT establish important rules concerning trade liberalization, intellectual property protection, technical standards and public health.

Judicial decisions such as EC – Biotech Products (2006), Canada – Pharmaceutical Patents (2000), US – Shrimp (1998), EC – Asbestos (2001) and Novartis AG v. Union of India (2013) demonstrate the importance of balancing international commercial interests with public health, environmental protection and intellectual property rights.

Therefore, an effective international trade law framework must promote fair competition, scientific innovation, regulatory transparency, environmental sustainability and equitable access to biotechnology products while respecting the legitimate regulatory authority of individual countries.

15. Important Case Laws for Examination

EC – Biotech Products (2006): GMO trade and approval procedures.

Canada – Pharmaceutical Patents (2000): TRIPS and pharmaceutical patent exceptions.

US – Shrimp (1998): Environmental protection and GATT Article XX.

EC – Asbestos (2001): Public health exceptions in international trade.

US – Gasoline (1996): National treatment and environmental regulation.

US – Tuna II (2012): Non-discriminatory technical regulations.

Novartis AG v. Union of India (2013): Pharmaceutical patents and access to medicines.

16. Important International Legal Instruments

General Agreement on Tariffs and Trade, 1994.

Agreement on Trade-Related Aspects of Intellectual Property Rights, 1994.

Agreement on Sanitary and Phytosanitary Measures, 1994.

Agreement on Technical Barriers to Trade, 1994.

General Agreement on Trade in Services, 1994.

Cartagena Protocol on Biosafety, 2000.

Convention on Biological Diversity, 1992.

Paris Convention for the Protection of Industrial Property, 1883.

Convention on International Trade in Endangered Species of Wild Fauna and Flora, 1973.

United Nations Convention on Contracts for the International Sale of Goods, 1980.

END OF TOPIC